- Home
- BCAT vs SPRY Comparison
BCAT vs SPRY Comparison
Compare BCAT & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAT
- SPRY
- Stock Information
- Founded
- BCAT 2020
- SPRY 2015
- Country
- BCAT United States
- SPRY United States
- Employees
- BCAT N/A
- SPRY N/A
- Industry
- BCAT Finance/Investors Services
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- BCAT Finance
- SPRY Health Care
- Exchange
- BCAT Nasdaq
- SPRY Nasdaq
- Market Cap
- BCAT 1.5B
- SPRY 1.8B
- IPO Year
- BCAT N/A
- SPRY N/A
- Fundamental
- Price
- BCAT $15.04
- SPRY $11.62
- Analyst Decision
- BCAT
- SPRY Strong Buy
- Analyst Count
- BCAT 0
- SPRY 4
- Target Price
- BCAT N/A
- SPRY $28.75
- AVG Volume (30 Days)
- BCAT 308.8K
- SPRY 2.3M
- Earning Date
- BCAT 01-01-0001
- SPRY 08-13-2025
- Dividend Yield
- BCAT 9.38%
- SPRY N/A
- EPS Growth
- BCAT N/A
- SPRY N/A
- EPS
- BCAT 1.43
- SPRY N/A
- Revenue
- BCAT N/A
- SPRY $112,339,000.00
- Revenue This Year
- BCAT N/A
- SPRY N/A
- Revenue Next Year
- BCAT N/A
- SPRY $182.40
- P/E Ratio
- BCAT $11.41
- SPRY N/A
- Revenue Growth
- BCAT N/A
- SPRY 22367.80
- 52 Week Low
- BCAT $13.67
- SPRY $10.00
- 52 Week High
- BCAT $16.38
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- BCAT 55.69
- SPRY 25.12
- Support Level
- BCAT $14.75
- SPRY $13.32
- Resistance Level
- BCAT $15.26
- SPRY $14.00
- Average True Range (ATR)
- BCAT 0.15
- SPRY 1.00
- MACD
- BCAT 0.01
- SPRY -0.30
- Stochastic Oscillator
- BCAT 71.79
- SPRY 9.88
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.